The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

18 Aug 2020 15:30

RNS Number : 4924W
Evgen Pharma PLC
18 August 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Evgen Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

SPREADEX LTD

City and country of registered office (if applicable)

St Albans, UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

07/08/2020

6. Date on which issuer notified (DD/MM/YYYY):

18/08/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.66%

2.63%

8.29%

137,297,441

Position of previous notification (if

applicable)

6.62%

1.11%

7.73%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BSVYN304

7,770,000

5.66%

SUBTOTAL 8. A

8,770,000

5.66%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

CFD/SPREADBET

3,610,500

2.63%

SUBTOTAL 8. B 1

3,610,500

2.63%

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

David Corben

01727895135

 

Place of completion

UK

Date of completion

18/08/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLZZGMRDRGGGZM
Date   Source Headline
22nd Mar 20217:00 amRNSAppointment of Chief Business Officer
15th Mar 20219:00 amRNSHolding(s) in Company
11th Mar 20217:00 amRNSUpdate on Data Safety Review - STAR COVID-19 trial
9th Mar 202111:35 amRNSHolding(s) in Company
8th Mar 20211:49 pmRNSHolding(s) in Company
5th Mar 20214:04 pmRNSHolding(s) in Company
5th Mar 20219:17 amRNSDirector dealing
3rd Mar 202112:10 pmRNSResult of General Meeting & Total Voting Rights
3rd Mar 20217:00 amRNSResult of Open Offer
26th Feb 20214:39 pmRNSHolding(s) in Company
17th Feb 20219:58 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSUpdate on patient recruitment
12th Feb 20217:00 amRNSPosting of Circular & Notice of GM
2nd Feb 20213:15 pmRNSPlacing and Open Offer to raise up to £11 million
22nd Jan 20217:00 amRNSPreclinical data on a new therapeutic target
21st Jan 20217:00 amRNSPositive pre-clinical data for lead asset SFX-01
19th Jan 20217:00 amRNSPatient recruitment update in STAR-COVID 19 trial
23rd Dec 20202:05 pmRNSSecond Price Monitoring Extn
23rd Dec 20202:00 pmRNSPrice Monitoring Extension
10th Dec 20207:00 amRNSHalf-year Report
27th Nov 20202:33 pmRNSHolding(s) in Company
27th Nov 20209:15 amRNSHolding(s) in Company
23rd Nov 20207:00 amRNSRecruitment of first patient in STAR trial
11th Nov 20207:00 amRNSComment on the COVID-19 vaccine announcement
6th Nov 20209:25 amRNSHolding(s) in Company
29th Oct 202011:55 amRNSHolding(s) in Company
29th Oct 20209:09 amRNSHolding(s) in Company
26th Oct 20203:00 pmRNSHolding(s) in Company
23rd Oct 20207:00 amRNSAll approvals received for STAR trial to commence
6th Oct 20207:00 amRNSGrant of options
24th Sep 20207:00 amRNSAppointment of Chief Executive Officer
15th Sep 20207:00 amRNSLicence agreement with Juvenescence
18th Aug 20203:30 pmRNSHolding(s) in Company
18th Aug 20203:25 pmRNSHolding(s) in Company
14th Aug 20204:41 pmRNSSecond Price Monitoring Extn
14th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
31st Jul 20203:40 pmRNSHolding(s) in Company
24th Jul 20209:47 amRNSShare option exercise and issue of equity
17th Jul 202012:05 pmRNSHolding(s) in Company
17th Jul 202012:02 pmRNSHolding(s) in Company
16th Jul 20202:52 pmRNSResult of AGM
7th Jul 202011:13 amRNSShare option exercise and issue of equity
6th Jul 20207:00 amRNSShare option exercise and issue of equity
23rd Jun 202011:44 amRNSHolding(s) in Company
23rd Jun 202011:38 amRNSHolding(s) in Company
19th Jun 20207:00 amRNSNotice of AGM
17th Jun 20209:38 amRNSHolding(s) in Company
17th Jun 20209:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.